2D Key-Event Joint Angles Across Phases of the Badminton Overhead Smash in Elite Colombian Players (BAD-2D-SMASH)

February 26, 2026 updated by: Édison Andrés Pérez Bedoya, Federal University of Vicosa

Preliminary Dominant-side 2D Key-event Joint-angle Descriptors Across Five Phases of the Badminton Overhead Smash in Elite Colombian Players: a Cross-sectional Exploratory Case Series

Phase-based descriptions of the badminton overhead smash can support coach-relevant feedback when laboratory motion capture is impractical. This cross-sectional exploratory case series characterises dominant-side, two-dimensional key-event joint-angle configurations (knee, hip, shoulder, elbow) across five phases (preparation, start, acceleration, impact, termination) in elite Colombian players from the Antioquia Badminton League. Athletes performed three maximal-effort smashes; one trial per athlete was selected for analysis using pre-defined visibility criteria, and one key-event frame per phase was digitised in Kinovea. Outcomes are descriptive phase-specific angle values and between-athlete dispersion metrics. The study is retrospectively registered for transparency.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Badminton overhead smash performance depends on coordinated whole-body contributions and is often judged qualitatively in applied settings. This study provides a field-based, minimal-equipment description of dominant-side planar joint-angle configurations across five technical phases of the overhead smash using a single lateral high-speed camera. Five elite athletes (men n=4; woman n=1) from the Antioquia Badminton League were recorded at 240 frames·s-¹ during maximal-effort smashes. Phases were defined as preparation (F1), start (F2), acceleration (F3), impact (F4), and termination (F5), with one key-event frame selected per phase. Knee, hip, shoulder, and elbow internal angles were extracted via three-point definitions in Kinovea. Data are reported descriptively (male subgroup as mean±SD and CV%; female case descriptively). The intention is to offer coach-interpretable phase references and to identify phases with higher inter-individual dispersion.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Colombia
    • Antioquia
      • Medellín, Antioquia, Colombia, 054080
        • Tecnológico de Antioquia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

High-performance adult badminton players from the Antioquia Badminton League (Colombia) with extensive competitive experience, assessed in a single session to describe 2D phase-based overhead smash joint-angle configurations.

Description

Inclusion Criteria:

  • 5 years of organised badminton experience
  • Current Antioquia Badminton League affiliation
  • Competitive participation in ≥5 federated tournaments
  • Previous selection to a representative team at least at national level
  • Able to execute maximal-effort overhead smashes on the testing day

Exclusion Criteria:

  • Pain or musculoskeletal complaints affecting upper limb, trunk, or lower limb on the testing day
  • Any condition preventing maximal-effort overhead smashes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Elite badminton players (Antioquia)
Elite badminton athletes from the Antioquia Badminton League (Colombia), aged ≥18 years, with >5 years of organised experience, competitive participation in ≥5 federated tournaments, and previous selection to at least national representative level. Participants completed a single testing session involving three maximal-effort overhead smashes recorded with a single lateral high-speed camera for 2D phase-based joint-angle extraction; no interventions were assigned.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
2D sagittal-plane joint angles at key events during the smash (knee, hip, shoulder, elbow)
Time Frame: Baseline (Visit 1; up to 30 minutes)
Internal joint angles (degrees) for the knee, hip, shoulder, and elbow computed using three-point (planar) definitions at five pre-defined key-event frames (F1-F5) spanning the smash phases. Angles will be extracted from lateral high-speed video after landmark digitisation in Kinovea using pre-specified anatomical landmarks and segment definitions. Data will be reported as mean (SD) for each joint and key-event frame; larger values indicate more extended joint configurations.
Baseline (Visit 1; up to 30 minutes)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Between-participant variability (SD and CV%) of 2D sagittal-plane joint angles by key-event frame and joint
Time Frame: Baseline (Visit 1; up to 30 minutes)
Between-participant dispersion of the 2D sagittal-plane joint angles (knee, hip, shoulder, elbow) at each pre-defined key-event frame (F1-F5). Variability will be summarized as (i) standard deviation (SD, degrees) and (ii) coefficient of variation (CV%, 100×SD/mean) across participants for each joint × key-event frame. Variability will be reported for the overall sample and, if applicable, stratified by sex as a pre-specified exploratory analysis.
Baseline (Visit 1; up to 30 minutes)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Federal University of Vicosa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 12, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 13, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 13, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 23, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 2, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 2, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Badminton-TdeA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared publicly because the sample is very small and drawn from an identifiable elite sports environment, meaning that de-identified records could still be re-identified when combined with contextual information. In addition, the source materials include video-derived measures, and participant consent was obtained for analysis and publication of aggregated results rather than unrestricted public release of participant-level data. Summary statistics and methodological details are reported in the publication; additional details may be considered on a case-by-case basis under a data-use agreement and ethics constraints.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings